Core Insights - Edwards Lifesciences emphasizes its leadership in structural heart innovation, aiming to enhance care for patients with structural heart disease [1] - The company announced the renewed vision for its global health initiative, Every Heartbeat Matters, targeting to assist 2 million additional patients facing barriers to access healthcare worldwide [1] Company Initiatives - The Every Heartbeat Matters initiative is part of Edwards' commitment to improving patient outcomes and expanding access to care [1] - The initiative reflects the company's deep expertise and strong partnerships in the healthcare sector [1]

Core Insights - Edwards Lifesciences will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with CFO Scott Ullem scheduled to speak at 9:50 a.m. ET [1] - The company announced that the U.S. District Court has granted the FTC's motion to block its proposed acquisition of JenaValve Technology, which Edwards believes would have benefited a significant patient population [1] - The FDA has approved Edwards Lifesciences' SAPIEN M3 mitral valve replacement system as the first transcatheter therapy using a transseptal approach for treating mitral regurgitation [1] Company Participation in Conferences - Edwards Lifesciences will participate in the J.P. Morgan Healthcare Conference on January 12, 2026, with CEO Bernard Zovighian and CFO Scott Ullem scheduled to present [1] Product Approvals and Innovations - The SAPIEN M3 mitral valve replacement system is indicated for symptomatic moderate-to-severe or severe mitral regurgitation in patients deemed unsuitable for surgery, marking a significant advancement in transcatheter therapies [1]